id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2022-E-2102-0007,FDA,FDA-2022-E-2102,Letter from FDA CDER to U. S. Patent and Trademark Office,Other,Letter(s),2025-01-13T05:00:00Z,2025,1,2025-01-13T05:00:00Z,,2025-01-13T20:03:44Z,,0,0,09000064868b7dfa
FDA-2022-E-2102-0006,FDA,FDA-2022-E-2102,Letter from U. S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2024-01-17T05:00:00Z,2024,1,2024-01-17T05:00:00Z,,2024-01-17T19:08:12Z,,0,0,090000648638a2b3
FDA-2022-E-2102-0005,FDA,FDA-2022-E-2102,Determination of Regulatory Review Period for Purposes of Patent Extension; EXKIVITY,Notice,Determinations,2023-12-08T05:00:00Z,2023,12,2023-12-08T05:00:00Z,2024-02-07T04:59:59Z,2023-12-08T13:44:24Z,2023-27004,0,0,09000064863164a4
FDA-2022-E-2102-0004,FDA,FDA-2022-E-2102,Letter from FDA CDER to U. S. Patent and Trademark Office,Other,Letter(s),2023-12-01T05:00:00Z,2023,12,2023-12-01T05:00:00Z,,2023-12-01T19:52:58Z,,0,0,09000064862d409c
FDA-2022-E-2102-0003,FDA,FDA-2022-E-2102,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2022-09-28T04:00:00Z,2022,9,2022-09-28T04:00:00Z,,2022-09-29T01:29:58Z,,0,0,090000648537b6b5
FDA-2022-E-2102-0001,FDA,FDA-2022-E-2102,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2022-09-01T04:00:00Z,2022,9,2022-09-01T04:00:00Z,,2022-09-01T12:31:37Z,,0,0,09000064852a2bdc
FDA-2022-E-2102-0002,FDA,FDA-2022-E-2102,Patent Extension Application from Honigman LLP (on behalf of Takeda Pharmaceutical Company Limited),Other,Application,2022-09-01T04:00:00Z,2022,9,2022-09-01T04:00:00Z,,2022-09-01T12:31:42Z,,0,0,09000064852a2854